[
  {
    "ts": null,
    "headline": "Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights",
    "summary": "SAN DIEGO, February 26, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.",
    "url": "https://finnhub.io/api/news?id=ee9579837afae70fc7779e4ff222adf0c0b76ee561994d23825b0fcddfda0b42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772139660,
      "headline": "Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights",
      "id": 139239923,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "SAN DIEGO, February 26, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.",
      "url": "https://finnhub.io/api/news?id=ee9579837afae70fc7779e4ff222adf0c0b76ee561994d23825b0fcddfda0b42"
    }
  },
  {
    "ts": null,
    "headline": "ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value",
    "summary": "By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Transaction enables exposure to both oral drug delivery program & medical device businesses Oramed Pharmaceuticals (NASDAQ:ORMP) recently signed a binding agreement for a transformative strategic transaction with Lifeward Ltd and another accredited investor. Lifeward is a medical device company focused on devices to aid physical",
    "url": "https://finnhub.io/api/news?id=e13891adf89157e7ef98e935598c383224299094fd8bab8d6c98c66766528733",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772122200,
      "headline": "ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value",
      "id": 139239924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Transaction enables exposure to both oral drug delivery program & medical device businesses Oramed Pharmaceuticals (NASDAQ:ORMP) recently signed a binding agreement for a transformative strategic transaction with Lifeward Ltd and another accredited investor. Lifeward is a medical device company focused on devices to aid physical",
      "url": "https://finnhub.io/api/news?id=e13891adf89157e7ef98e935598c383224299094fd8bab8d6c98c66766528733"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients",
    "summary": "Bristol Myers reports that Phase 3 breast cancer trial meets key goals, showing improved survival over chemotherapy options.",
    "url": "https://finnhub.io/api/news?id=362a763feafa91355cb7633806847ee579ec43cefe20e064aed94e5e64d5cc73",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772119583,
      "headline": "Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients",
      "id": 139248750,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/26/Breast-cancer.jpeg?width=2048&height=1536",
      "related": "BMY",
      "source": "Benzinga",
      "summary": "Bristol Myers reports that Phase 3 breast cancer trial meets key goals, showing improved survival over chemotherapy options.",
      "url": "https://finnhub.io/api/news?id=362a763feafa91355cb7633806847ee579ec43cefe20e064aed94e5e64d5cc73"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=a4e71b3c34b733557a5de03b9beddd0faa1a404f1c54e7517c14a13d5cfcd1e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772117404,
      "headline": "Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?",
      "id": 139237186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=a4e71b3c34b733557a5de03b9beddd0faa1a404f1c54e7517c14a13d5cfcd1e3"
    }
  },
  {
    "ts": null,
    "headline": "RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View",
    "summary": "Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.",
    "url": "https://finnhub.io/api/news?id=fd50a2eca5152ddb4297938c4aa8b500f072c0c5dd9f19735dc0f6d00a66a19a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772116680,
      "headline": "RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View",
      "id": 139237187,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.",
      "url": "https://finnhub.io/api/news?id=fd50a2eca5152ddb4297938c4aa8b500f072c0c5dd9f19735dc0f6d00a66a19a"
    }
  },
  {
    "ts": null,
    "headline": "SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer",
    "summary": "REDMOND, Wash. & PRINCETON, N.J., February 26, 2026--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treated Unresectable...",
    "url": "https://finnhub.io/api/news?id=806caeca553a2a133344d1db3afe256701fb3a892e1573f62d15b85c8e980ba5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772107140,
      "headline": "SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer",
      "id": 139232259,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "REDMOND, Wash. & PRINCETON, N.J., February 26, 2026--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treated Unresectable...",
      "url": "https://finnhub.io/api/news?id=806caeca553a2a133344d1db3afe256701fb3a892e1573f62d15b85c8e980ba5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer",
    "summary": "The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth.",
    "url": "https://finnhub.io/api/news?id=b7ce60d87d56be3d45cf3781f70b89a84a9863dcf49c06e5380e325139148812",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772105395,
      "headline": "Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer",
      "id": 139237188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth.",
      "url": "https://finnhub.io/api/news?id=b7ce60d87d56be3d45cf3781f70b89a84a9863dcf49c06e5380e325139148812"
    }
  },
  {
    "ts": null,
    "headline": "SystImmune And Bristol Myers Squibb Announce SystImmune's Sichuan Biokin Reports Topline Results From Pre-Specified Interim Analysis Of Phase III Study Evaluating Iza-Bren In Patients With Unresectable TNBC",
    "summary": "Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (&#34;PFS&#34;) and overall survival (&#34;OS&#34;) in an interim analysis of a Phase 3 trial (NCT06382142) conducted in ChinaBL-B01D1-307 is",
    "url": "https://finnhub.io/api/news?id=ef9cda6587c24d1e0dd4c33e257af75cbd58ecdf2d3f43b5ab11bfba2ce49690",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772093474,
      "headline": "SystImmune And Bristol Myers Squibb Announce SystImmune's Sichuan Biokin Reports Topline Results From Pre-Specified Interim Analysis Of Phase III Study Evaluating Iza-Bren In Patients With Unresectable TNBC",
      "id": 139231948,
      "image": "",
      "related": "BMY",
      "source": "Benzinga",
      "summary": "Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (&#34;PFS&#34;) and overall survival (&#34;OS&#34;) in an interim analysis of a Phase 3 trial (NCT06382142) conducted in ChinaBL-B01D1-307 is",
      "url": "https://finnhub.io/api/news?id=ef9cda6587c24d1e0dd4c33e257af75cbd58ecdf2d3f43b5ab11bfba2ce49690"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Bristol-Myers Squibb Company (NYSE:BMY) with a Sector Perform rating and a $60 price target. The firm said Bristol Myers has “large-cap pharma’s most significant Phase 3 path,” pointing to […]",
    "url": "https://finnhub.io/api/news?id=d945b2775ceb8903c5de562210b046d96f0ae1b395893f8e02656db376f94467",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772074646,
      "headline": "RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth",
      "id": 139227952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Bristol-Myers Squibb Company (NYSE:BMY) with a Sector Perform rating and a $60 price target. The firm said Bristol Myers has “large-cap pharma’s most significant Phase 3 path,” pointing to […]",
      "url": "https://finnhub.io/api/news?id=d945b2775ceb8903c5de562210b046d96f0ae1b395893f8e02656db376f94467"
    }
  }
]